



# Representative Legal Matters

Michael Pilo

Prior to joining Baker McKenzie, Michael advised on the following matters:

## Equity Offerings

- Informatica's\* USD 841 million initial public offering and USD 408 million follow-on offering
- BioAge's USD 238 million initial public offering and concurrent private placement
- bluebird bio's\* USD 500 million follow-on offering
- Cerulean Pharma's\* USD 60 million initial public offering
- Change Healthcare's USD 640.7 million initial public offering
- Clementia Pharmaceuticals'\* USD 120 million initial public offering and USD 70.26 million follow-on offering
- Dimension Therapeutics'\* USD 71.5 million initial public offering
- Habit Restaurants' USD 90 million initial public offering and USD 154.8 million follow-on offering
- Idera Pharmaceuticals'\* USD 50 million initial public offering
- Karyopharm Therapeutics'\* USD 108.8 million initial public offering
- Kiniksa Pharmaceuticals'\* USD 152.6 million initial public offering
- LogicBio Therapeutics' USD 70 million initial public offering and USD 50 million follow-on offering
- Madrigal Pharmaceuticals'\* USD 129.42 million follow-on offering
- Moderna's\* USD 604.3 million initial public offering and USD 1.34 billion follow-on offering
- Momenta Pharmaceuticals'\* USD 225 million initial public offering
- nCino's\* USD 250 million initial public offering
- Planet Fitness' USD 1.275 billion securitized financing facility transaction
- Proteostasis Therapeutics'\* USD 50 million initial public offering
- Quanterix's\* USD 64.13 million initial public offering and USD 60 million follow-on offering
- Radius Health's\* USD 300 million follow-on offering



- Relay Therapeutics’\* USD 400 million initial public offering
- Sarepta Therapeutics’ USD 350 million follow-on offering
- Seres Therapeutics’\* USD 225.75 million follow-on offering
- Sixth Street Specialty Lending’s\* USD 86.6 million follow-on offering
- Surgery Partners’ USD 271.2 million initial public offering
- TherapeuticsMD’s\* USD 125 million follow-on offering

#### **High Yield Bond Offerings**

- Karyopharm Therapeutics’\* USD 150 million convertible senior notes offering
- NFP’s USD 200 million debt financing

#### **SPAC Transactions**

- Nextdoor’s business combination with Khosla Ventures Acquisition Co. II
- Altimeter Growth’s USD 450 million initial public offering
- Ares Acquisition’s\* USD 870 million initial public offering
- Ascendant Digital Acquisition’s\* USD 360 million initial public offering
- Carney Technology Acquisition’s\* USD 350 million initial public offering
- Fortress Capital Acquisition’s\* USD 350 million initial public offering
- Jiya Acquisition’s\* USD 100 million initial public offering
- Juniper Industrial Holding’s USD 300 million initial public offering
- Montes Archimedes Acquisition’s\* USD 400 million initial public offering
- Reinvent Technology Partners’\* USD 600 million initial public offering
- Reinvent Technology Partners 2’s\* USD 200 million initial public offering
- Sustainable Development Acquisition I’s USD 275 million initial public offering
- TCW Special Purpose Acquisition’s USD 450 million initial public offering

\*Representing the Representatives on behalf of the Underwriters/Initial Purchasers, including such investment banks as Goldman Sachs, Morgan Stanley, J.P. Morgan, Barclays, BofA Securities, Citigroup, Cowen, Credit Suisse, Deutsche Bank and Leerink, among others.